The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight
Journal of Pharmacy & Pharmaceutical Sciences · 25.06.2026 · 29
DOI: 10.3389/jpps.2026.16610 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 25.06.2026. Verfasst von Esraa M Mosalam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan. Hauptthemen laut MEDLINE: Neoplasms, Phosphatidylethanolamine Binding Protein, PTEN Phosphohydrolase, Glycogen Synthase Kinase 3 beta. Die Arbeit nennt 299 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Imam Muhammad Ibn Saud Islamic University.
Abstract (Originalsprache)
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. The Raf kinase inhibitor protein (RKIP) has been reported to be under expressed in many cancers and plays a role in the regulation of tumor cells’ survival, proliferation, invasion, and metastasis, hence, a tumor suppressor. RKIP also regulates tumor cell resistance to cytotoxic drugs/cells. Likewise, the tumor suppressor, phosphatase and tensin homolog (PTEN), which inhibits the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) pathway, is either mutated, under expressed, or deleted in many cancers and shares with RKIP its anti-tumor properties and its regulation in resistance. Several pathways are regulated by RKIP, GSK-3, PTEN, and the transcriptional and post-transcriptional regulations of RKIP, GSK-3, and PTEN are significantly altered in cancers. In addition, RKIP, GSK-3 and PTEN play a key role in the regulation of tumor cells response to chemotherapy and immunotherapy. In this review, we will focus on the roles that GSK-3, PTEN, and RKIP play in various human cancers. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mechanistic target of rapamycin complex 1 (mTORC1), nuclear Factor kappa-B (NF-κB)/Snail family transcriptional repressor 1 (Snail)/Yin Yang 1 (YY1) loop, and rat sarcoma virus oncogene (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
- Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat, Egypt.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
- Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
- Pharmacy Practice Department, Faculty of Pharmacy, Mansoura National University, Gamasa, Egypt.
Förderung
- Al-Imam Muhammad Ibn Saud Islamic University
Zitieren
APA
Mosalam, E. M., Abdallah, M. S., Gardouh, A. R., Hamza, E., Bahaa, M. M., Nazih, M., Al-Dhelaan, R. A., & Kamal, N. (2026). The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight. Journal of Pharmacy & Pharmaceutical Sciences, 29. https://doi.org/10.3389/jpps.2026.16610
Vancouver
Mosalam EM, Abdallah MS, Gardouh AR, Hamza E, Bahaa MM, Nazih M, et al. The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight. Journal of Pharmacy & Pharmaceutical Sciences. 2026;29. doi:10.3389/jpps.2026.16610
BibTeX
@article{Mosalam2026,
author = {Mosalam, Esraa M and Abdallah, Mahmoud S and Gardouh, Ahmed R and Hamza, Eman and Bahaa, Mostafa M and Nazih, Mahmoud and Al-Dhelaan, Reham A and Kamal, Noha},
title = {The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
volume = {29},
doi = {10.3389/jpps.2026.16610}
}
EUVIMED